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Biochemical diagnosis and monitoring of Neuroblastoma in Vietnam: 
Development of homovanillic and vanillylmandelic acid analysis by gas 
chromatography - mass spectrometry and establishment of reference intervals 
 
Highlights 
 
 A cost effective and robust testing method for simultaneous quantitation of 
urinary HVA and VMA by GCMS was developed.  
 Age - related reference intervals for random urine HVA and VMA samples 
were established for Vietnamese children. 
 The intervals declined progressively with increasing age for each analyte. 
 The appropriate assignment of the upper reference interval for these 
biomarkers will ensure maximum specificity for neuroblastoma diagnosis and 
treatment monitoring. 
*Highlights (for review)
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Abstract 
Objectives:  The aim of this study was to develop an accurate robust testing 
method to simultaneously measure urine levels of HVA and VMA using gas 
chromatography mass spectrometry (GCMS) and to establish age-specific 
reference intervals of HVA and VMA in random urines for Vietnamese children. 
Design and Methods:  The assay for urinary HVA and VMA was developed and 
incorporated the internal standard 3-phenyl butyric acid, liquid-liquid extraction 
with ethyl acetate, derivatization with BSTFA followed by gas chromatographic 
separations with mass spectrometric detection in single ion monitoring mode. 
Reference intervals were developed from random urine samples collected from 
634 disease free Vietnamese children and compared to 50 known neuroblastoma 
patient samples.  Results were reported relative to creatinine concentration.  Age 
related 95% reference intervals for urinary HVA and VMA were estimated from 
sample quantiles. 
Results: Method validation studies were performed prior to the establishment of 
the Vietnamese age related reference intervals for urinary HVA and VMA per 
mmol creatinine.  HVA for children <6 months (n=91) was 6.2-36.1 μmol/mmol; 6 
months to <1 year (n=141) was 3.7 to 25.9 μmol/mmol; 1 to 5 years (n=139) was 
3.5 to 16.5 μmol/mmol; 6 to 10 years (n=136) was 2.7-8.3 μmol/mmol; and 11 to 
15 years (n=127) was 1.3-8.9 μmol/mmol.  VMA for children <6 months was 2.0-
11.9 μmol/mmol; 6 months to <1 year was 1.7-9.1 μmol/mmol; 1 to 5 years was 
2.1-7.4 μmol/mmol; 6 to 10 years was 1.7-4.4 μmol/mmol; and 11 to 15 years 
was 0-6.0 μmol/mmol. 
Conclusions:  A robust testing method for simultaneous quantitation of urinary 
HVA and VMA by GCMS was developed.  This method is accurate, precise and 
fit for its clinical purpose and suitable for developing countries.  Age - related 
reference intervals of random urinary HVA and VMA were established for 
Vietnamese children and the intervals declined progressively with increasing age 
for each analyte. 
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INTRODUCTION 
Neuroblastoma, a neuroblastic tumor derived from primordial neural crest, is the 
most common extracranial solid tumor in childhood, and the most frequent 
diagnosed in infancy.  If detected early enough, neuroblastoma is curable.  
Biochemically early diagnosis of the tumor can be done by determination of 
various biomarkers excreted continuously in elevated amounts in the urine of 
infants [1]. 
Neuroblastoma is characterized biochemically by the elevation of the urine 
catecholamine dopamine and catecholamine metabolites, particularly 
homovanillic (HVA) and vanillylmandelic acid (VMA).  In over 92% of cases of 
neuroblastoma the presence of the tumor is accompanied by an increase in 
urinary HVA and / or VMA excretion.[2]  Therefore, the measurement of these 
biomarkers is important in the diagnosis and monitoring of patients with 
neuroblastoma.   
These biomarkers are routinely measured in developed countries by high 
performance liquid chromatography (HPLC) with electrochemical detection (ECD) 
and more recently with mass spectrometry (MS) detection.  Such instrumentation 
is not routinely used in the Vietnamese hospital setting.  In Vietnam, previously 
these analytes could not be measured and instead VMA by colorimetric analysis 
was performed. However, gas chromatography coupled mass spectrometry 
(GCMS) detection is newly available (since 2010) and we proposed to develop a 
method based on a traditional GCMS organic acids method [3]. 
The aim of this study was to develop a robust testing method to simultaneously 
measure urine levels of HVA and VMA using the GCMS at the National Hospital 
of Pediatrics (NHP) and to establish age-specific reference intervals of HVA and 
VMA in random urines for Vietnamese children. 
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MATERIALS AND METHOD 
Sample collection 
Random urine samples were collected from 634 disease free children in pre-
schools and schools around Hanoi Vietnam.  These included 91 children less 
than 6 months, 141 from 6 months to less than 1 year, 139 from 1 to 5 years and 
136 from 6 to 10 years, and 127 from 11 to 15 years.  Fifty known neuroblastoma 
urine samples from patients attending the Oncology Department and Outpatient 
Clinic at NHP were also collected for comparison.  
Urine samples were collected and divided into two graduated plastic tubes from 
each participant.  The first tube contained 1 ml of HCl 6 mol/L, and urine was 
added to exactly obtain the total volume of 10 ml.  Each tube was tested to 
ensure adequate acidification and the protocol required that any urine samples 
with a pH greater than 3.0 were discarded (n=0).  The second tube i.e. plain tube 
was used for creatinine determination.  Samples were transported on cold packs 
to the laboratory within 2 hours of collection.  Samples were stored at -20oC until 
testing and analyzed in batches.  Because of adding HCl for urine HVA and VMA 
conservation, the final results were obtained by multiplying the first results with a 
dilution factor. 
 
Measurement of HVA and VMA 
Materials 
HVA, VMA (pure chemicals) were purchased from Sigma (Sigma –Aldrich 
Chemie GmbH, Riedstrasse 2 D-89555 Steinheim, Germany).  Urine Calibrator 
Lyophylised for VMA/HVA/5-HIAA was obtained from Recipe (Recipe Chemicals 
+ Instruments GmbH, Munich, Germany) and Lyphochek Quantitative Urine 
Controls were from Bio-Rad (Bio-Rad, Marnes- la- Coquette, France). N,O-
bis(trimethylsilyl)trifluoroacetamide (BSTFA) was from Supelco (Supelco, 
Bellfonte, USA). All other solvents and reagents of analytical grade were 
obtained from Merck (Merck KGaA, Darmstadr, Germany). 
 
Gas chromatography/ mass spectrometry  
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An Agilent (Agilent Technologies, Inc. 5301 Stevens Creek Boulevard Santa 
Clara, CA 95052, USA) Model 7890A gas chromatograph coupled to an Agilent 
5975C Mass Selective Detector was used.  The gas chromatograph was 
equipped with a HP-5MS fused- silica capillary column (30m x 0.25 mm id x 0.25 
µm film thickness) from Agilent.  Helium was used as the carrier gas.  The initial 
column temperature was 160oC, held for 3 min, followed by an increase at 8oC 
min-1 in first ramp, 50oC min-1 in second ramp held for 3.5 min, to final 
temperature 280ºC.  The total run time was 15.7 min.  The transfer line between 
the GC and MS systems was kept at 290oC.  The ion source temperature was 
230oC. 
 
Sample preparation and derivatization with BSTFA 
A 50 µl aliquot of the internal standard solution (containing 5 mM 3-phenyl butyric 
acid in 20 mM sodium bicarbonate) was added to 1 ml urine sample.  This 
solution was acidified with 2 drops of concentrated HCl (37%), to which a spatula 
of NaCl was added to form a saturated solution. After mixing, this solution was 
extracted with 3 ml of ethyl acetate.  The tubes were shaken vigorously for 5 
minutes, then centrifuged and the upper layer (organic layer) was carefully 
removed using a glass pipette.  The organic extracts were dried under a stream 
of nitrogen. 200 µl of BSTFA was added and sealed vials were incubated at 80oC 
for 75 minutes.  After that the vials were cooled to room temperature and the 
derivatized samples were transferred onto autosampler vials and 1 µl was split 
injected (split ratio 1:5) onto the GCMS. 
 
HVA, VMA and creatinine quantitation 
The method was calibrated with Recipe Urine Calibrator Lyophylised for 
VMA/HVA/5-HIAA and internally controlled with Bio-Rad Lyphochek Quantitative 
urine controls.  The target ions were 267 m/z for HVA, 371m/z for VMA and 236 
m/z for internal standard.  The qualifier ions were 326m/z for HVA, 297m/z for 
VMA and 221m/z for the internal standard.  Formal method validation studies 
were conducted prior to method implementation.  To confirm comparability of 
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results with other laboratories in the Australasian region, we participated in the 
RCPAQAP Urine Chemistry external quality assurance program. 
 
Urine creatinine was measured as a mechanism to correct for concentration.  
Urine creatinine was measured by Jaffe kinetic method on Beckman Coulter 
AU2700 chemistry analyser (Beckman Coulter, Mishima, Japan).  Patient results 
were reported relative to creatinine concentration. 
 
Analytical method validation 
Calibration graphs for HVA and VMA were established by using three level 
standards.  The calibration curve was updated each time to minimize the variable 
conditions.  The calibration curve was plotted and the results of the quality control 
and samples were computed.  The method validation studies included linearity, 
sensitivity, imprecision and recovery experiments. 
Limit of Qantitation: The limit of quantification was determined by 
analyzing serial diluted standards.  The diluted standards were assayed 
five times in a single run according to the standard operation procedures.4 
Linearity: Two pooled urine samples from children were prepared.  One 
(from healthy children) close to the detection limit and the other (from 
neuroblastoma patients) near the expected upper limit of the dynamic 
range.  The five mixtures were prepared by mixing the low pool and the 
high pool with different ratios.  Three replicate measurements for each 
specimen were done.  The mean of the measured values and the 
assigned values were plotted on the linearity graph and inspected for a 
linear relationship.[5] 
Imprecision: The within - batch imprecision was determined by assaying 
two levels of urine quality control in a single batch (n=15).  The between- 
batch imprecision was estimated by analyzing two levels of urine quality 
control (n= 20) over a period of 3 months.  
Recovery: For the recovery study, pooled urine from healthy individuals 
was divided into two aliquots.  One aliquot was spiked with the standard 
solution.  The volume of standard added to the sample was less than 10% 
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of that of the pooled urine so that the major disruption of the sample 
matrix was avoided.  The other aliquot was spiked with 0.2 m/L HCl (the 
solvent for preparing standards).  The two aliquots were then analyzed.  
Five measurements on each aliquot reduced the effects of the imprecision 
of method. 
 
Ethics Approval 
Ethical approval for collection and analysis of urine samples was obtained from 
the Ethics Committee at the National Hospital of Pediatrics, Hanoi Vietnam.  
Informed consent was obtained for all study participants. 
 
Statistical analysis and development of reference intervals: 
One-way analysis of variance (ANOVA) was used to determine if sub-grouped 
reference intervals were required for gender and age.  Due to non-normality, 95% 
reference intervals for urinary HVA and VMA were estimated from the sample’s 
2.5th and 97.5th percentile.  Nonparametric bootstrapping methods were 
employed to generate 95% confidence intervals around sample reference 
intervals.  
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RESULTS 
A urine HVA and VMA GCMS method was developed to diagnose and monitor 
Neuroblastoma.  The chromatography and MS ions monitored in a male urine 
sample are displayed in Figure 1. 
Analytical method validation 
Prior to analysis of the study urine samples, the method was fully validated using 
protocols from Westgard’s Method Validation Textbook.[5]  The results of the 
method validation studies demonstrated that the assay was fit for its clinical 
purpose.  Specific studies conducted were: 
Limit of quantitation 
The limit of quantitation for both analytes was 0.9 µmol/L. 
Linearity  
HVA and VMA were linear to at least 193 and 221 µmol/L, respectively.  
The linear regression for HVA was y= x – 0.1031. The linear regression 
for VMA was y= 0.9974 x +  0.1951. 
Imprecision  
Using Bio-Rad Lyphochek Quantitative control urine (n= 15 at each level), 
the within batch coefficients of variation (CVs) were, respectively, 2.45% at 
11 µmol/L and 1.20% at 88 µmol/L for HVA, 2.97% at 18.2 µmol/L and 
1.79% at 90.6 µmol/L for VMA.  The between batch CVs, calculated over 
20 consecutive procedures in a 3 month period were 3.6% at 11 µmol/L 
and 2.1% at 88 µmol/L for HVA, 6.6% at 18.2 µmol/L  and 2.6% at 90.6 
µmol/L for VMA. 
Recovery 
Two urines spiked with aqueous standard were used to determine 
recovery.  Recovery for HVA at 38.8 µmol/L and VMA at 27.2 µmol/L were 
96% and 92% respectively. 
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HVA and VMA reference intervals 
The study design collected a total of 684 reference samples from five age groups 
and 50 samples from neuroblastoma patients (Table 1). 
Prior to estimating reference intervals (RIs), the differences between age band 
and gender means were assessed to determine if RIs were required to be sub-
grouped for HVA/Creatinine and VMA/Creatinine.  The initial step was to fit a two-
way factorial analysis of variance (ANOVA) model predicting HVA/Creatinine and 
VMA/Creatinine using both age bands and gender.  However, the Levene’s test 
of homogeneity of variance for these models indicated heteroscedasticity for both 
HVA/Creatinine, F(9, 624) = 18.90, p< .001 and VMA/Creatinine, F(9, 624) = 
10.57, p< .001. 
Transformations were explored to correct for heteroscedasticity in the models, 
but no satisfactory solutions were found.  Therefore, the next strategy was to 
apply a robust Brown-Forsythe method to test the main effects for age bands 
using one-way ANOVA.  The results of these main effect tests were statistically 
significant for both HVA/Creatinine, F(4, 256.98) = 214.13, p< .001, and 
VMA/Creatinine, F(4, 315.20) = 97.11, p< .001.  Follow-up pairwise comparisons 
for using Dunnett’s T3 correction for unequal variance revealed all age bands for 
HVA/Creatinine differed significantly from each other (p < .001).  This suggested 
that all age bands should remain in their sub-groups for RI estimation. 
To determine if age bands should be further divided by gender, individual two-
sample tests were used to compare means between males and females for each 
age category.  A Bonferroni corrected significance level of α = 0.05/5 = 0.01 was 
used to control for inflated type I error across these tests.  The results of the two-
sample t-tests found no significant differences between genders on mean 
HVA/Creatinine across the five age bands (all p-values > .01). These results 
suggested that the reference intervals did not need to be sub-divided by gender.  
Hence the male and female samples per age group were combined (Figure 2a). 
The same process was repeated for the statistically significant Brown-Forsythe 
corrected one-way ANOVA for VMA/Creatinine.  Dunnett’s T3 multiple 
comparisons found that all age bands differed significantly from each other 
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except for “< 6 months” vs. “6 months < 1 year”, p = .227 and “6 – 10.9 years” 
vs. “11 – 15 years”, p = 0.017 (Compared to a Bonferroni corrected significance 
level of 0.01).  These results suggested that these age bands could be combined, 
however, to be consistent with HVA/Creatinine, all five age bands were retained.  
The two-sample t-tests comparing means between genders across age bands 
were all not statistically significant.  Gender sub-groups were not required for 
VMA/Creatinine.(Figure 2b) 
Reference intervals for HVA/Creatinine and VMA/Creatinine across the five age 
bands, < 6 Months, 6 Months < 1, 1 - 5 Years, 6 - 10 Years, 11 – 15 are reported 
in Table 2.  As a comparison, intervals for known Neuroblastoma patients were 
also calculated for comparison.  Reference intervals (RI) were defined as the 
points where 95% of measurements will fall such that 2.5% fall below or above 
the lower and upper cut-offs respectively.  The cut-offs would correspond to 
estimates of the 2.5 and 97.5 percentile of the population.  Due to non-normality, 
95% Bootstrapped [6] confidence intervals for the lower and upper values of the 
references intervals were calculated (Table 2).  
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DISCUSSION  
In this study we successfully developed the urinary HVA - VMA GCMS method 
based on a classical organic acid profile using a cheaper (non-isotopic) internal 
standard.  We proved that high selectivity and sensitivity of gas chromatography/ 
mass spectrometry make this technique very suitable for the determination of 
HVA and VMA in a complex matrix such in urine.  The advantages of the method 
include its fast run time (15.7 minutes), noninvasive sample collection (of random 
urine), small sample volume (1000 µL of urine), simple sample preparation and 
cost-effectiveness.  In addition, the method is accurate and precise with the 
added advantage of being cheap.  The linearity of the method covers the 
decision levels of urinary HVA and VMA in diagnosing neuroblastoma.  This is a 
superior alternative to the routine method used before in our laboratory; 
quantitation of VMA by colorimetric analysis. 
The traditional methods for analysis of HVA and VMA include spectrophotometric 
techniques and gas and liquid chromatography.  Unfortunately, the 
spectrophotometric methods have poor specificity and for this reason, have been 
replaced by chromatography methods.  Liquid chromatography - based methods 
are the most frequently used.[7]  Many of these chromatographic methods 
employ fluorescence, electrochemistry or mass spectrometry detection to permit 
simultaneous measurement of both HVA and VMA.[8]  GC-MS methods are also 
quite sensitive and specific and can detect both HVA and VMA simultaneously 
[8]. 
Conventionally twenty four hour (24h) urine samples were used for analysis, 
whilst some studies reported using random urine.  Obtaining a complete 
collection, especially in young infants, is difficult to obtain, time consuming, 
inconvenient for patients and staff, and lead to higher cost.  In addition, children 
presenting with a suspected neuroblastoma, need rapid investigation and 
treatment.  Since neuroblastoma is the most frequent solid tumor in childhood 
and represents up to 50% solid tumors in the first year of life, a reliable but rapid 
diagnostic strategy to diagnose neuroblastoma in such patients is needed.[9]  
Thus the age related reference interval of HVA and VMA were established using 
random urine samples and GCMS method developed in this study.  We used 
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random urine because of the difficulties of collecting 24h urine samples from 
small children.  Random urine samples can be collected easily and there is 
evidence that this is a valid alternative to timed or 24h urine collections.[10] 
When using random urine samples to determine reference intervals for HVA and 
VMA, it is essential to adjust for difference in urinary dilution.  Creatinine, which is 
excreted in the urine at a roughly constant rate, can be used to help make this 
adjustment. In this study, the reference intervals were constructed based upon 
the ratios HVA/Creatinine and VMA/Creatinine.  The reference data (Table 2) 
demonstrate that there is a higher excretion of HVA and VMA relative to 
creatinine early in infancy.  The importance of establishing reliable population 
specific reference intervals for HVA and VMA is highlighted by the possible 
improvement in prognosis for neuroblastoma with early detection. 
Age specific reference intervals for HVA/creatinine and VMA/creatinine have 
been previously established in other pediatric populations.  Some of these 
studies employed GC without MS detection whilst others used HPLC with various 
detection systems.  Age stratification also varied between these studies. 
Some previously studies on other populations have demonstrated similar 
reference intervals and age stratification to our study.  Tuchman et. al. using 
capillary GC reported random urinary HVA and VMA reference intervals for 
seven age groups with very low numbers of subjects in each age group.[10]  Our 
values of HVA and VMA for children less than 1 year old were higher but for 
other groups our results were similar to those of Tuchman.[10]  Kellie et al. also 
used untimed urine samples for HVA and VMA determination [9].  The upper limit 
of HVA for children less than one year old was also lower than our value, but the 
value of other age groups were similar.  The upper limit of VMA for all age groups 
was higher than that of ours.  Both studies established reference intervals for 
random urine HVA and VMA using non-neuroblastoma pediatric patients, with all 
groups greater than one year old mirroring our reference interval data.  
Fitzgibbon et. al. previously reported the reference values for urinary HVA and 
VMA in healthy children.[11]  The method used was HPLC with electrochemical 
detection.  Henderson et. al. using the capillary GC with flame ionization 
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detection published the reference ranges for HVA and VMA excretion in non-
neurobastoma pediatric patients.[12]  The upper limits of HVA and VMA in these 
studies are similar to our values.  Together, these studies potentially indicate that 
the reference intervals for HVA and VMA are consistent across ethnic cohorts 
greater than one year of age. 
A number of previous reference interval studies indicate different reference 
intervals to the ones we report here.  Soldin et. al. using HPLC method published 
HVA and VMA reference values on random urine samples from birth to 20 
years.[13]  Their upper limit for children of all age groups are lower than that of 
ours.  The method that these authors used was different to our method, which 
may explain the difference seen between the studies.  Recently, Davidson et al. 
reported the observed ranges for urinary catecholamine and metabolites in 
random urine specimens from children.[14]  They used HPLC with 
electrochemical detection for measuring HVA and VMA and the age grouping 
was also different to our study.  The upper limit of HVA for children less than 1 
year was similar to ours but the upper limit of VMA for all age groups seems to 
higher than that of ours.  Together these studies highlight the caution required 
when differences in methodology and lack of uniformity in age grouping exists.  
Our study is the first to look at reference intervals in association with a mass 
selective detection method. 
The purpose of this study was to establish age-specific reference intervals of 
HVA and VMA in random urines for Vietnamese children.  Urinary random HVA 
and VMA in 50 patients with neuroblastoma are compared with reference 
intervals.  Urinary excretion of HVA exceeded the highest reference value in 45 
diagnosed patients (90%) and VMA exceeded the highest reference value in 41 
diagnosed patients (82%).  Several authors reported that HVA is more 
consistently elevated in neuroblastoma and that 20% to 30% of patients with 
neuroblastoma excrete normal amounts of VMA.[9]  The table 2 indicated there 
was an overlap between the excretion of HVA and VMA by unaffected children 
and children with known neuroblastoma on treatment.  It has been reported that 
10% - 15% of histologically proven cases of neuroblastoma are not associated 
with any increase in excretion of these metabolites.[15,16]  Whilst the exact 
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upper limit of the reference interval is now defined for random urine HVA and 
VMA per mmol creatinine due to this lack of sensitivity , clearly elevated values of 
HVA and VMA are diagnostic but borderline or normal results cannot be used to 
exclude neuroblastoma.  However, the appropriate assignment of the upper 
reference interval for these biomarkers will ensure maximum specificity. 
Conclusion 
A robust testing method for the simultaneous quantitation of urinary HVA and 
VMA by GCMS was developed.  This method is accurate, precise and could be 
suitable in developing countries where the stable isotope is too expensive.  The 
age - related reference intervals of urinary HVA and VMA were established for 
Vietnamese children and the values declined progressively with increasing age 
for each analyte. 
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Tables  
Table 1. Reference Interval Study Groups consisting of 634 normative and 50 
know neuroblastoma patients. 
Groups 
Age Gender 
N M SD 
Male Female 
Count % Count % 
 
< 6 months 91 0.27 0.13 35 38.5% 56 61.5% 
6 months < 1 year 141 0.71 0.15 59 41.8% 82 58.2% 
1 - 5.9 years 139 3.62 1.22 66 47.5% 73 52.5% 
6 - 10.9 years 136 8.30 1.23 64 47.1% 72 52.9% 
11 - 15 years 127 13.26 1.24 72 56.7% 55 43.3% 
 Neuroblastoma 50 3.46 1.91 22 44.0% 28 56.0% 
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Table 2. Reference Interval Estimates and 95% Bootstrapped Confidence Intervals for HVA/Creatinine and VMA/Creatinine 
      Reference Interval Estimates
a 
Outcome Age Band N Mean SD Median Lower Upper 
HVA/Creatinine < 6 Months 91 17.70 6.99 17.08 6.17 36.1 
      (3.90, 8.58) (27.43, 39.66) 
 6 Months < 1 141 13.24 5.30 12.96 3.74 25.91 
      (1.83, 5.06) (20.86, 31.62) 
 1 - 5 Years 139 6.85 3.29 5.96 3.50 16.5 
      (2.94, 4.09) (12.85, 20.79) 
 6 - 10 Years 136 4.54 1.79 4.14 2.73 8.25 
      (2.37, 2.86) (7.00, 9.73) 
 11 - 15 Year 127 3.42 1.96 2.92 1.24 9.03 
      (0.96, 1.63) (6.28, 14.18) 
 Neuroblastoma 50 126.87 143.33 71.05 5.56 510.14 
      (3.80, 15.0) (337.1, 579.1) 
VMA/Creatinine < 6 Months 91 6.10 2.69 5.60 2.04 11.94 
      (1.74, 2.80) (10.70, 16.48) 
 6 Months < 1 141 5.38 1.83 5.36 1.65 9.05 
      (0.26, 2.64) (8.13, 9.73) 
 1 - 5 Years 139 3.62 1.27 3.28 2.09 7.36 
      (1.55, 2.36) (5.91, 8.57) 
 6 - 10 Years 136 2.82 1.06 2.66 1.70 4.36 
      (1.45, 1.87) (3.88, 6.49) 
 11 - 15 Year 127 2.31 1.51 2.05 0.02 5.62 
      (0.01, 0.20) (4.05, 6.99) 
 Neuroblastoma 50 83.06 103.63 46.55 2.34 313.59 
      (1.70, 4.87) (180.1, 560.8) 
a 
95% CI from 1000 Bootstrapped samples are reported in brackets 
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Figures Legend 
 
Figure 1a: Total Ion Chromatogram (TIC) of the urine sample taken from a 
neuroblastoma patient 
 
Figure 1b. Electron Impact (EI) mass spectra of HVA 
 
Figure 1c. Electron impact (EI) mass spectra of VMA 
 
Figure 2a – Box plots for HVA/Creatinine (umol/mmol) across age bands. Circles 
represent outliers and stars represent extreme outliers. Outliers give all age band 
distributions a positive skew. Variance decreases with age.  
 
Figure 2b – Box whisker plots VMA/creatinine (umol/mmol) across age bands. 
Circles represent outliers and stars represent extreme outliers. Outliers give all 
age band distributions a positive skew. Variance decreases with age.  
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Figure 1a: Total Ion Chromatogram (TIC) of the urine sample taken from a 
neuroblastoma patient 
 
 
 
Figure 1b. Electron Impact (EI) mass spectra of HVA 
 
 
 
Figure 1c. Electron impact (EI) mass spectra of VMA 
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Figure 2a – Box plots for HVA/Creatinine (umol/mmol) across age bands. Circles 
represent outliers and stars represent extreme outliers. Outliers give all age band 
distributions a positive skew. Variance decreases with age.  
 
 
Figure 2b – Box whisker plots VMA/creatinine (umol/mmol) across age bands. 
Circles represent outliers and stars represent extreme outliers. Outliers give all 
age band distributions a positive skew. Variance decreases with age.  
